: Children and young adult with high grade gliomas (HGG) have dismal prognoses and treatment options remain limited. We present 19 patients diagnosed with anaplastic astrocytoma (AA) or glioblastoma (GBM) treated with concomitant and adjuvant 20-30 mg/m2/dose of vinorelbine and 30 mg/kg/day valproic acid (VA) in combination to consolidated TMZ and focal RT after maximal surgery. We evaluated the feasibility of treating children diagnosed with HGG. The median follow-up time was 51.4 months (range, 6.2-106.6 months). The 5-year OS was 57.9% (CI 95%, 33.2-76.3) and the 5-year PFS was 57.9% (CI 95%, 33.2-76.3). Eight patients (42.1%) have progressed so far, with a median time to progression of 9 months from diagnosis (range, 4.6-34.7 months). All of them died for disease progression. At time of analysis, 11 patients were still alive with no evidence of disease. It is notable that all events occurred within 35 months from the start of therapy. All 19 treated patients reported low-grade drug-related adverse events (AEs). The treatment was well tolerated in our limited cohort of patients without significant toxicity. Further studies of the efficacy and safety of combination of vinorelbine/VA to consolidated RT/TMZ therapy in children with HGG are underway in a clinical trial setting.

Brief report: pediatric high-grade gliomas treated with vinorelbine and valproic acid added to temozolomide / Guidi, Milena; Giunti, Laura; Buccoliero, Anna Maria; Fonte, Carla; Scoccianti, Silvia; Censullo, Maria Luigia; Caporalini, Chiara; Tellini, Marco; Di Nicola, Marco; Castelli, Barbara; Greto, Daniela; Giordano, Flavio; Genitori, Lorenzo; Sardi, Iacopo. - In: AMERICAN JOURNAL OF CANCER RESEARCH. - ISSN 2156-6976. - ELETTRONICO. - 13:(2023), pp. 3668-3678.

Brief report: pediatric high-grade gliomas treated with vinorelbine and valproic acid added to temozolomide

Guidi, Milena
Writing – Original Draft Preparation
;
Giunti, Laura;Buccoliero, Anna Maria;Fonte, Carla;Scoccianti, Silvia;Censullo, Maria Luigia;Caporalini, Chiara;Tellini, Marco;Castelli, Barbara;Greto, Daniela;Giordano, Flavio;Sardi, Iacopo
2023

Abstract

: Children and young adult with high grade gliomas (HGG) have dismal prognoses and treatment options remain limited. We present 19 patients diagnosed with anaplastic astrocytoma (AA) or glioblastoma (GBM) treated with concomitant and adjuvant 20-30 mg/m2/dose of vinorelbine and 30 mg/kg/day valproic acid (VA) in combination to consolidated TMZ and focal RT after maximal surgery. We evaluated the feasibility of treating children diagnosed with HGG. The median follow-up time was 51.4 months (range, 6.2-106.6 months). The 5-year OS was 57.9% (CI 95%, 33.2-76.3) and the 5-year PFS was 57.9% (CI 95%, 33.2-76.3). Eight patients (42.1%) have progressed so far, with a median time to progression of 9 months from diagnosis (range, 4.6-34.7 months). All of them died for disease progression. At time of analysis, 11 patients were still alive with no evidence of disease. It is notable that all events occurred within 35 months from the start of therapy. All 19 treated patients reported low-grade drug-related adverse events (AEs). The treatment was well tolerated in our limited cohort of patients without significant toxicity. Further studies of the efficacy and safety of combination of vinorelbine/VA to consolidated RT/TMZ therapy in children with HGG are underway in a clinical trial setting.
2023
13
3668
3678
Guidi, Milena; Giunti, Laura; Buccoliero, Anna Maria; Fonte, Carla; Scoccianti, Silvia; Censullo, Maria Luigia; Caporalini, Chiara; Tellini, Marco; Di Nicola, Marco; Castelli, Barbara; Greto, Daniela; Giordano, Flavio; Genitori, Lorenzo; Sardi, Iacopo
File in questo prodotto:
File Dimensione Formato  
ajcr0013-3668.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 516.74 kB
Formato Adobe PDF
516.74 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1328991
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact